Nyxoah SA (NASDAQ:NYXH – Get Free Report) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 298,468 shares, a decline of 63.9% from the June 15th total of 826,117 shares. Based on an average trading volume of 309,898 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.9% of the shares of the company are short sold.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Nyxoah in a research note on Monday, March 23rd. Robert W. Baird set a $2.85 price target on shares of Nyxoah in a report on Thursday. Weiss Ratings lowered shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Stifel Nicolaus decreased their price objective on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a research report on Wednesday, June 17th. Finally, Piper Sandler reissued an “overweight” rating and set a $7.00 target price (down from $9.00) on shares of Nyxoah in a research note on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $5.96.
Read Our Latest Report on NYXH
Institutional Trading of Nyxoah
Nyxoah Stock Performance
Shares of NYXH stock opened at $1.71 on Monday. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.99 and a quick ratio of 0.88. The company has a market cap of $66.28 million, a price-to-earnings ratio of -0.69 and a beta of 1.61. The stock has a 50 day simple moving average of $2.26 and a 200-day simple moving average of $3.41. Nyxoah has a 1-year low of $1.26 and a 1-year high of $8.59.
Nyxoah (NASDAQ:NYXH – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.11. The firm had revenue of $7.38 million for the quarter, compared to analyst estimates of $7.05 million. Nyxoah had a negative return on equity of 163.73% and a negative net margin of 543.21%. On average, equities research analysts expect that Nyxoah will post -1.67 EPS for the current fiscal year.
Nyxoah Company Profile
Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.
The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.
Featured Articles
- Five stocks we like better than Nyxoah
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
